Tag: MONOGRAPH

  • NMN (Nicotinamide Mononucleotide)

    NAD+ precursor

    A direct precursor of NAD+ and the molecule directly downstream of NAMPT, the rate-limiting enzyme of NAD+ salvage; popularized by David Sinclair for longevity applications.

    Abstract

    NMN (ฮฒ-nicotinamide mononucleotide; CAS 1094-61-7; molecular formula C11H15N2O8P; molecular weight 334.22) is the immediate precursor of NAD+ in the salvage biosynthesis pathway, generated by phosphorylation of nicotinamide riboside by NRK kinases or by NAMPT-mediated condensation of nicotinamide with PRPP. NMN was popularized by David Sinclair’s group at Harvard as a longevity supplement for raising NAD+ levels, which decline with age. The compound is converted to NAD+ through NMNAT enzymes after cell uptake (presumed via Slc12a8 transporter or via dephosphorylation to NR with separate uptake). Animal studies show NMN supplementation reverses several age-related phenotypes (vascular, metabolic, neurological) by restoring NAD+ levels. Human clinical trials have shown plasma NAD+ elevation but clinical endpoint changes are modest. The compound is sold as a dietary supplement; FDA classified NMN as a drug investigation in 2022, complicating supplement market availability.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Idebenone

    Synthetic ubiquinone analog

    A short-chain synthetic ubiquinone analog approved in Europe for Leber hereditary optic neuropathy, with reduced lipophilicity and better water solubility than CoQ10.

    Abstract

    Idebenone (Raxone, Catena, Sovrima; CAS 58186-27-9; molecular formula C19H30O5; molecular weight 338.44) is a synthetic short-chain ubiquinone analog with the 10-carbon isoprenoid tail of CoQ10 replaced by a 10-carbon hydroxyalkyl chain. The structural modification substantially increases water solubility while preserving the redox-cycling quinone chemistry. The compound is approved in Europe (Raxone) for Leber hereditary optic neuropathy, a mitochondrial complex I disease producing acute optic neuropathy. Idebenone bypasses dysfunctional Complex I by directly transferring electrons from cytosolic NADH to Complex III. The compound has also been studied in Alzheimer disease (mixed results, did not advance to FDA approval), Friedreich ataxia (modest effects, no approval), and Duchenne muscular dystrophy.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Kisspeptin

    Hypothalamic neuropeptide / KISS1R agonist

    An endogenous neuropeptide encoded by the KISS1 gene, master regulator of GnRH neuron firing and reproductive function.

    Abstract

    Kisspeptin (kisspeptin-54 and shorter active fragments including kisspeptin-10; encoded by the KISS1 gene) is an endogenous peptide identified in 2003 as the master regulator of GnRH neuron firing in the hypothalamus, controlling reproductive function and pubertal onset. Loss-of-function mutations in KISS1 or its receptor KISS1R produce hypogonadotropic hypogonadism. Exogenous kisspeptin administration stimulates LH and FSH release through GnRH neuron activation. The compound has been studied as a fertility therapeutic (induction of ovulation in functional hypothalamic amenorrhea) and as a research probe for reproductive neuroendocrine function. Pharmacokinetics: plasma half-life of kisspeptin-54 is ~30 minutes; kisspeptin-10 has shorter half-life. Research doses are highly variable; clinical trial doses range 0.01 to 6.4 nmol/kg IV.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • DHEA (Dehydroepiandrosterone)

    Endogenous androgen precursor

    An endogenous adrenal steroid hormone with androgenic and neurosteroid activity; declines with age and supplemented for hormone restoration.

    Abstract

    DHEA (dehydroepiandrosterone; CAS 53-43-0; molecular formula C19H28O2; molecular weight 288.42) is an endogenous adrenal steroid hormone produced by the adrenal cortex. DHEA and its sulfate (DHEAS) are the most abundant circulating steroid hormones in young adults; both decline progressively with age, reaching 10 to 20 percent of peak by age 70. The compound is a precursor for downstream androgen and estrogen synthesis and is also a sigma-1 receptor ligand and NMDA receptor PAM with neurosteroid activity. Supplementation has been studied for adrenal insufficiency, depression in older adults, sexual dysfunction, and cognitive function with mixed results. The compound is sold as a dietary supplement in the United States but is prescription-only or banned in many other jurisdictions.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Boswellia serrata

    Frankincense gum resin / boswellic acids

    An Indian frankincense resin containing boswellic acids with selective 5-lipoxygenase inhibition for inflammatory conditions.

    Abstract

    Boswellia serrata (Indian frankincense) is a tree resin used in Ayurvedic medicine for inflammatory conditions, particularly osteoarthritis and inflammatory bowel disease. Active constituents are boswellic acids (acetyl-11-keto-beta-boswellic acid, AKBA, being the most pharmacologically characterized). Mechanism is selective inhibition of 5-lipoxygenase (5-LOX), reducing leukotriene synthesis.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • EGCG (Epigallocatechin Gallate)

    Tea catechin polyphenol

    The principal catechin polyphenol of green tea with broad antioxidant and anti-inflammatory activity.

    Abstract

    EGCG (epigallocatechin-3-gallate; CAS 989-51-5; molecular formula C22H18O11; molecular weight 458.37) is the principal catechin polyphenol of green tea, accounting for 50 to 80 percent of total catechin content in unfermented tea. The compound has broad pharmacological activity: direct antioxidant, anti-inflammatory through NF-kB inhibition, modulation of multiple cancer-related pathways, and modest cardiovascular and metabolic effects. Bioavailability is poor; plasma EGCG concentrations after oral administration are low.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Maprotiline

    Tetracyclic norepinephrine reuptake inhibitor

    A tetracyclic NRI with TCA-like side effects but selective noradrenergic action; significant seizure risk at high dose.

    Abstract

    Maprotiline (N-methyl-9,10-ethanoanthracene-9(10H)-propylamine; CAS 10262-69-8; molecular formula C20H23N; molecular weight 277.40) is a tetracyclic norepinephrine reuptake inhibitor developed at Ciba-Geigy and approved in the US in 1980 under the trade name Ludiomil. NET affinity is approximately 11 nM with very weak SERT activity (Ki greater than 1 microM), making the compound a selective NRI structurally classed with the tetracyclics owing to its bridged anthracene scaffold. Significant H1 (Ki approximately 2 nM) and muscarinic activity produces a side effect profile resembling tricyclic antidepressants: sedation, anticholinergic effects, weight gain. Plasma half-life is 21 to 52 hours, the longest of the antidepressant class, owing to the bridged scaffold’s resistance to CYP metabolism. The seizure risk and TCA-like adverse profile have led to declining use in favor of mirtazapine and SSRIs.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Clozapine

    Atypical antipsychotic / D4-D2 multireceptor antagonist

    The prototype atypical antipsychotic; the gold standard for treatment-resistant schizophrenia, limited by agranulocytosis risk requiring weekly blood monitoring.

    Abstract

    Clozapine (8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; CAS 5786-21-0; molecular formula C18H19ClN4; molecular weight 326.82) is a dibenzodiazepine atypical antipsychotic developed at Wander/Sandoz and approved by the FDA in 1989 under the trade name Clozaril. The compound is the prototype atypical antipsychotic, introducing the receptor profile that defines the class: weak D2 antagonism (Ki approximately 130 nM) combined with potent 5-HT2A antagonism (Ki approximately 16 nM), producing antipsychotic efficacy without the extrapyramidal symptoms typical of high-affinity D2 antagonists. Off-target activity is broad: H1, alpha-1, muscarinic M1-M5 (Ki approximately 7 nM at M1), 5-HT2C, 5-HT3, 5-HT6, 5-HT7 antagonism, contributing to sedation, weight gain, sialorrhea (paradoxical from M4 partial agonism), and orthostatic hypotension. The defining clinical feature is efficacy in treatment-resistant schizophrenia, where clozapine consistently outperforms other antipsychotics; the limitation is approximately 1 percent agranulocytosis incidence, requiring weekly CBC monitoring through the first 6 months and biweekly thereafter. Plasma half-life is 12 hours; metabolism is via CYP1A2 (primary), CYP3A4, CYP2D6. Used as the canonical atypical antipsychotic in mechanism studies and as the gold standard for treatment-resistant schizophrenia.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Gepirone

    5-HT1A partial agonist

    An azapirone 5-HT1A partial agonist developed for major depressive disorder; FDA-approved in 2023 after a 30-year development cycle.

    Abstract

    Gepirone (4,4-dimethyl-1-{4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl}-2,6-piperidinedione; CAS 83928-76-1; molecular formula C19H29N5O2; molecular weight 359.47) is an azapirone 5-HT1A partial agonist developed by Bristol-Myers Squibb and Fabre-Kramer over a 30-plus-year development cycle, ultimately approved by the FDA in 2023 under the trade name Exxua for major depressive disorder. The compound is structurally and mechanistically similar to buspirone: 5-HT1A affinity approximately 19 nM with intrinsic activity approximately 60 percent; minimal D2 affinity; active metabolite 1-PP. Distinct from buspirone in development trajectory (positioned for depression rather than anxiety) and in being formulated as extended-release for once-daily dosing. The approved indication is MDD; the principal selling point versus SSRIs is absence of sexual dysfunction (a major SSRI tolerability complaint). Plasma half-life is 18 hours (ER formulation); metabolism is via CYP3A4. Used as a reference 5-HT1A partial agonist with depression-focused clinical development.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • RU58841

    Topical androgen receptor antagonist

    A topical non-steroidal AR antagonist developed for androgenetic alopecia; never advanced to commercial development but widely used as a research compound.

    Abstract

    RU58841 (PSK3841; CAS 154992-24-2; molecular formula C17H18F3N3O3; molecular weight 369.34) is a non-steroidal androgen receptor antagonist developed at Roussel-Uclaf (now Sanofi) in the 1990s as a topical treatment for androgenetic alopecia. The compound is structurally a hydantoin and binds the AR with sufficient affinity to compete with DHT in scalp tissue. Topical application allows local AR antagonism in hair follicles with minimal systemic absorption, theoretically avoiding the sexual side effects of systemic 5AR inhibitors. Phase 1 and 2 trials demonstrated efficacy in slowing or reversing scalp hair loss. Development was discontinued at Roussel-Uclaf (subsequent corporate merger and prioritization). The compound entered the research-grade and DIY hair loss community via the published patents and has remained in informal use without regulatory approval. Used as a reference topical AR antagonist in dermatologic and androgen pharmacology research.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.